Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Queensland Health
Daiichi Sankyo
Johnson and Johnson
AstraZeneca
McKinsey
Deloitte
Express Scripts
Dow

Generated: July 17, 2018

DrugPatentWatch Database Preview

ARNUITY ELLIPTA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Arnuity Ellipta patents expire, and what generic alternatives are available?

Arnuity Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are eight patents protecting this drug.

This drug has two hundred and sixty-three patent family members in forty-one countries.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.
Drug patent expirations by year for ARNUITY ELLIPTA
Generic Entry Opportunity Date for ARNUITY ELLIPTA
Generic Entry Date for ARNUITY ELLIPTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
POWDER;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ARNUITY ELLIPTA
Synonyms for ARNUITY ELLIPTA
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-DIFLUORO-14-{[(FLUOROMETHYL)SULFANYL]CARBONYL}-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL FURAN-2-CARBOXYLATE
(6|A,11|A,16|A,17|A)-6,9-Difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioic Acid S-(Fluoromethyl) Ester
(6alpha,11alpha,14beta,16alpha,17alpha)-6,9-Difluoro-17-{[(Fluoromethyl)sulfanyl]carbonyl}-11-Hydroxy-16-Methyl-3-Oxoandrosta-1,4-Dien-17-Yl Furan-2-Carboxylate
397864-44-7
6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate
779352-12-4
911210-90-7
Alisade
Allermist
Avamys
BDBM50354851
CHEBI:74899
DB08906
DTXSID60228586
Flonase Sensimist
Flonase Sensimist Allergy Relief
Fluticasone fuorate
Fluticasone furancarboxylate
Fluticasone furoate
Fluticasone furoate (JAN/USAN/INN)
Fluticasone furoate [USAN:INN]
FLUTICASONEFUROATE
fluticasonum furoas
FT-0668768
Furamist
furoate de fluticasone
furoato de fluticasona
GSK 685 698
GSK 685698
GW 685698
GW 685698X
GW-685698
GW-685698X
GW6
gw685698
GW685698X
JS86977WNV
PL010437
SCHEMBL140504
UNII-JS86977WNV
Veramyst
Veramyst (TN)
ZINC3992105

US Patents and Regulatory Information for ARNUITY ELLIPTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline ARNUITY ELLIPTA fluticasone furoate POWDER;INHALATION 205625-003 May 17, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline ARNUITY ELLIPTA fluticasone furoate POWDER;INHALATION 205625-002 Aug 20, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Glaxosmithkline ARNUITY ELLIPTA fluticasone furoate POWDER;INHALATION 205625-001 Aug 20, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Glaxosmithkline ARNUITY ELLIPTA fluticasone furoate POWDER;INHALATION 205625-001 Aug 20, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ARNUITY ELLIPTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline ARNUITY ELLIPTA fluticasone furoate POWDER;INHALATION 205625-001 Aug 20, 2014 ➤ Sign Up ➤ Sign Up
Glaxosmithkline ARNUITY ELLIPTA fluticasone furoate POWDER;INHALATION 205625-002 Aug 20, 2014 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ARNUITY ELLIPTA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,144,845 Compounds useful in the manufacture of an anti-inflammatory androstane derivative ➤ Sign Up
6,777,400 Anti-inflammatory androstane derivative compositions ➤ Sign Up
6,787,532 Formulation containing anti-inflammatory androstane derivatives ➤ Sign Up
6,537,983 Anti-inflammatory androstane derivatives ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for ARNUITY ELLIPTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008 00022 Denmark ➤ Sign Up
2008000029 Germany ➤ Sign Up PRODUCT NAME: FLUTICASONFUROAT UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/07/434/001-003 20080111
C/GB08/026 United Kingdom ➤ Sign Up PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
C0014 France ➤ Sign Up PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Covington
Boehringer Ingelheim
McKesson
Mallinckrodt
Queensland Health
Express Scripts
Dow
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.